Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The working hypothesis is that oral rigosertib treatment when added to platinum-based
Chemoradiotherapy (CRT) will improve progression-free survival for first-line patients with
intermediate- or high-risk human papillomavirus negative positive (HPV (+)) Head and Neck
Squamous Cell Carcinoma. This study will determine the highest safe dose of oral rigosertib
that can be used with cisplatin and CRT. This study will also record any side effects that
may occur and measure tumor sizes and how long patients live.